secwatch.observer — SEC 8-K summary
======================================

Issuer:     VOLITIONRX LTD (VNRX)
CIK:        0000093314
Form:       8-K
Filed at:   2024-09-16T23:59:59+00:00
Accession:  0001477932-24-005745
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VolitionRx markets oncology portfolio for out-licensing via PharmaVentures
--------------------------------------------------------------------------

- Company engaged PharmaVentures as licensing adviser; document made available to third parties starting September 16, 2024.
- Document provides brief introduction to certain components of the oncology portfolio; no specific assets or terms disclosed.
- No revenue, deal value, or counterparty announced; no financial impact provided.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/93314/000147793224005745/0001477932-24-005745-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/93314/000147793224005745/vnrx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-24-005745

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer